Does the media refer more to IRWD or AGEN?

In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than Agenus. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Ironwood Pharmaceuticals' score of 0.78 indicating that Agenus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, AGEN or CBIO?

Agenus has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 1.17 $120K $1.59 2.03 Crescent Biopharma $10.84M 45.71 -$153.94M -$10.91 N/A

Is AGEN or CBIO more profitable?

Agenus has a net margin of 50.49% compared to Crescent Biopharma's net margin of 0.00%. Agenus' return on equity of -31.66% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Crescent Biopharma N/A -103.44% -88.19%

Does the media favor AGEN or CBIO?

In the previous week, Crescent Biopharma had 2 more articles in the media than Agenus. MarketBeat recorded 4 mentions for Crescent Biopharma and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Crescent Biopharma's score of 0.96 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, RIGL or AGEN?

Rigel Pharmaceuticals has higher revenue and earnings than Agenus. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rigel Pharmaceuticals $294.28M 1.90 $367.02M $18.72 1.62 Agenus $114.20M 1.17 $120K $1.59 2.03

Does the media prefer RIGL or AGEN?

In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Agenus. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Rigel Pharmaceuticals' score of 0.54 indicating that Agenus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACHV or AGEN more profitable?

Agenus has a net margin of 50.49% compared to Achieve Life Sciences' net margin of 0.00%. Agenus' return on equity of -31.66% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -193.49% -111.88% Agenus 50.49% -31.66% 42.71%

Does the media favor ACHV or AGEN?

In the previous week, Achieve Life Sciences had 2 more articles in the media than Agenus. MarketBeat recorded 4 mentions for Achieve Life Sciences and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Achieve Life Sciences' score of 0.80 indicating that Agenus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, XOMA or AGEN?

XOMA Royalty has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.03 $31.71M $1.57 26.56 Agenus $114.20M 1.17 $120K $1.59 2.03

Is XOMA or AGEN more profitable?

XOMA Royalty has a net margin of 53.46% compared to Agenus' net margin of 50.49%. XOMA Royalty's return on equity of 12.56% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% Agenus 50.49% -31.66% 42.71%

Does the media refer more to XOMA or AGEN?

In the previous week, XOMA Royalty and XOMA Royalty both had 2 articles in the media. Agenus' average media sentiment score of 1.26 beat XOMA Royalty's score of 0.94 indicating that Agenus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Agenus (AGEN) Competitors

$3.22 -0.16 (-4.73%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$3.24 +0.02 (+0.78%)

As of 06/3/2026 07:49 PM Eastern

Compare

AGEN vs. IRWD, CBIO, RIGL, ACHV, and XOMA

Should you buy Agenus stock or one of its competitors? MarketBeat compares Agenus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agenus include Ironwood Pharmaceuticals (IRWD), Crescent Biopharma (CBIO), Rigel Pharmaceuticals (RIGL), Achieve Life Sciences (ACHV), and XOMA Royalty (XOMA). These companies are all part of the "biotechnology" industry.

How does Agenus compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, suggesting a potential upside of 92.39%. Agenus has a consensus price target of $23.00, suggesting a potential upside of 614.29%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than Agenus. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Ironwood Pharmaceuticals' score of 0.78 indicating that Agenus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Agenus has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

61.5% of Agenus shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ironwood Pharmaceuticals has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	1.78	$24.02M	$0.60	5.40
Agenus	$114.20M	1.17	$120K	$1.59	2.03

Agenus has a net margin of 50.49% compared to Ironwood Pharmaceuticals' net margin of 28.26%. Agenus' return on equity of -31.66% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Agenus	50.49%	-31.66%	42.71%

Summary

Ironwood Pharmaceuticals beats Agenus on 9 of the 17 factors compared between the two stocks.

How does Agenus compare to Crescent Biopharma?

Agenus (NASDAQ:AGEN) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Agenus has a net margin of 50.49% compared to Crescent Biopharma's net margin of 0.00%. Agenus' return on equity of -31.66% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Crescent Biopharma	N/A	-103.44%	-88.19%

Agenus presently has a consensus target price of $23.00, suggesting a potential upside of 614.29%. Crescent Biopharma has a consensus target price of $28.00, suggesting a potential upside of 55.73%. Given Agenus' higher possible upside, equities analysts clearly believe Agenus is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Agenus has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.17	$120K	$1.59	2.03
Crescent Biopharma	$10.84M	45.71	-$153.94M	-$10.91	N/A

In the previous week, Crescent Biopharma had 2 more articles in the media than Agenus. MarketBeat recorded 4 mentions for Crescent Biopharma and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Crescent Biopharma's score of 0.96 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

61.5% of Agenus shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 5.5% of Agenus shares are held by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Agenus beats Crescent Biopharma on 11 of the 17 factors compared between the two stocks.

How does Agenus compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rigel Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Agenus has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Agenus. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Rigel Pharmaceuticals' score of 0.54 indicating that Agenus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals presently has a consensus target price of $54.50, indicating a potential upside of 79.87%. Agenus has a consensus target price of $23.00, indicating a potential upside of 614.29%. Given Agenus' higher possible upside, analysts clearly believe Agenus is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rigel Pharmaceuticals has higher revenue and earnings than Agenus. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	1.90	$367.02M	$18.72	1.62
Agenus	$114.20M	1.17	$120K	$1.59	2.03

Rigel Pharmaceuticals has a net margin of 121.50% compared to Agenus' net margin of 50.49%. Rigel Pharmaceuticals' return on equity of 47.99% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Agenus	50.49%	-31.66%	42.71%

Summary

Rigel Pharmaceuticals beats Agenus on 11 of the 16 factors compared between the two stocks.

How does Agenus compare to Achieve Life Sciences?

Achieve Life Sciences (NASDAQ:ACHV) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Achieve Life Sciences currently has a consensus target price of $14.67, suggesting a potential upside of 198.41%. Agenus has a consensus target price of $23.00, suggesting a potential upside of 614.29%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Achieve Life Sciences had 2 more articles in the media than Agenus. MarketBeat recorded 4 mentions for Achieve Life Sciences and 2 mentions for Agenus. Agenus' average media sentiment score of 1.26 beat Achieve Life Sciences' score of 0.80 indicating that Agenus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a net margin of 50.49% compared to Achieve Life Sciences' net margin of 0.00%. Agenus' return on equity of -31.66% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Agenus	50.49%	-31.66%	42.71%

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 5.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Agenus has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Agenus	$114.20M	1.17	$120K	$1.59	2.03

Achieve Life Sciences has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Agenus has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Summary

Agenus beats Achieve Life Sciences on 11 of the 16 factors compared between the two stocks.

How does Agenus compare to XOMA Royalty?

XOMA Royalty (NASDAQ:XOMA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 8.9% of XOMA Royalty shares are held by company insiders. Comparatively, 5.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

XOMA Royalty has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Agenus has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

In the previous week, XOMA Royalty and XOMA Royalty both had 2 articles in the media. Agenus' average media sentiment score of 1.26 beat XOMA Royalty's score of 0.94 indicating that Agenus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XOMA Royalty has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.03	$31.71M	$1.57	26.56
Agenus	$114.20M	1.17	$120K	$1.59	2.03

XOMA Royalty has a net margin of 53.46% compared to Agenus' net margin of 50.49%. XOMA Royalty's return on equity of 12.56% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
Agenus	50.49%	-31.66%	42.71%

XOMA Royalty currently has a consensus price target of $53.75, suggesting a potential upside of 28.90%. Agenus has a consensus price target of $23.00, suggesting a potential upside of 614.29%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

XOMA Royalty beats Agenus on 8 of the 14 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGEN vs. The Competition

Export

Metric	Agenus	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$140.75M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	2.03	17.78	22.17	24.18
Price / Sales	1.17	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	-0.39	6.63	9.84	6.72
Net Income	$120K	$24.20M	$3.57B	$337.19M
7 Day Performance	-5.29%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-42.81%	45.50%	26.49%	33.10%

Agenus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGEN Agenus	2.3308 of 5 stars	$3.22 -4.7%	$23.00 +614.3%	-35.6%	$140.75M	$114.20M	2.03	440	Positive News
IRWD Ironwood Pharmaceuticals	2.4608 of 5 stars	$3.46 -3.1%	$6.23 +80.2%	+431.2%	$582.12M	$296.15M	5.77	220	Analyst Revision
CBIO Crescent Biopharma	2.069 of 5 stars	$19.72 -4.5%	$28.00 +42.0%	N/A	$569.05M	$10.84M	N/A	50
RIGL Rigel Pharmaceuticals	3.1831 of 5 stars	$29.86 -2.1%	$54.50 +82.5%	+48.6%	$564.13M	$294.28M	1.60	160	Analyst Forecast
ACHV Achieve Life Sciences	2.5568 of 5 stars	$5.30 +1.1%	$14.67 +176.7%	+16.7%	$537.93M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGEN) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agenus (AGEN) Competitors

AGEN vs. IRWD, CBIO, RIGL, ACHV, and XOMA

How does Agenus compare to Ironwood Pharmaceuticals?

Summary

How does Agenus compare to Crescent Biopharma?

Summary

How does Agenus compare to Rigel Pharmaceuticals?

Summary

How does Agenus compare to Achieve Life Sciences?

Summary

How does Agenus compare to XOMA Royalty?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agenus (AGEN) Competitors

AGEN vs. IRWD, CBIO, RIGL, ACHV, and XOMA

How does Agenus compare to Ironwood Pharmaceuticals?

Do analysts prefer IRWD or AGEN?

Does the media refer more to IRWD or AGEN?

Which has more volatility & risk, IRWD or AGEN?

Do insiders and institutionals hold more shares of IRWD or AGEN?

Which has higher valuation and earnings, IRWD or AGEN?

Is IRWD or AGEN more profitable?

Summary

How does Agenus compare to Crescent Biopharma?

Is AGEN or CBIO more profitable?

Do analysts rate AGEN or CBIO?

Which has higher valuation and earnings, AGEN or CBIO?

Does the media favor AGEN or CBIO?

Which has more risk and volatility, AGEN or CBIO?

Do insiders & institutionals have more ownership in AGEN or CBIO?

Summary

How does Agenus compare to Rigel Pharmaceuticals?

Do insiders and institutionals believe in RIGL or AGEN?

Which has more risk & volatility, RIGL or AGEN?

Does the media prefer RIGL or AGEN?

Do analysts rate RIGL or AGEN?

Which has better earnings & valuation, RIGL or AGEN?

Is RIGL or AGEN more profitable?

Summary

How does Agenus compare to Achieve Life Sciences?

Do analysts recommend ACHV or AGEN?

Does the media favor ACHV or AGEN?

Is ACHV or AGEN more profitable?

Do insiders & institutionals believe in ACHV or AGEN?

Which has better earnings and valuation, ACHV or AGEN?

Which has more risk & volatility, ACHV or AGEN?

Summary

How does Agenus compare to XOMA Royalty?

Do insiders and institutionals believe in XOMA or AGEN?

Which has more risk & volatility, XOMA or AGEN?

Does the media refer more to XOMA or AGEN?

Which has stronger earnings & valuation, XOMA or AGEN?

Is XOMA or AGEN more profitable?

Do analysts recommend XOMA or AGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools